How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2.
Antibodies (Basel)
; 9(3)2020 Sep 04.
Article
em En
| MEDLINE
| ID: mdl-32899722
We examined the kinetics and mechanisms by which monoclonal antibodies (mAbs) utilize complement to rapidly kill targeted cancer cells. Based on results from flow cytometry, confocal microscopy and high-resolution digital imaging experiments, the general patterns which have emerged reveal cytotoxic activities mediated by substantial and lethal Ca2+ fluxes. The Ca2+ fluxes are common to the reported pathways that have been utilized by other toxins in killing nucleated cells. These reactions terminate in very high levels of cell killing, and based on these considerations, we suggest additional strategies to further enhance mAb-based targeting of cancer with complement.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Antibodies (Basel)
Ano de publicação:
2020
Tipo de documento:
Article